Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Manuel Magallanes-Maciel"'
Autor:
Jeronimo Rafael Rodríguez-Cid, Saul Campos-Gomez, Vanessa García-Montes, Manuel Magallanes-Maciel, Rodrigo Rafael Flores-Mariñelarena, Valeria Michelle Fernández-Garibay, Iván Romarico González-Espinoza, Juan Paulo Ceja-García, Juan Carlos Cázarez-Price, Luis Martínez-Barrera, Leopoldo Barriguete-Parra, Carlos Jose Zuloaga-Fernandez, Roberto Kuri-Exsome, David Suárez-García, Jorge Ignacio Gonzalez-Villanueva, Noé Flores-Anaya, Jose Antonio Acevedo-Delgado, Alma Magdalena Astorga-Ramos, Raquel Gerson-Cwilich, Alberto Villalobos-Prieto, Claudia Rodríguez-Silva, Maria Fernanda Noriega-Iriondo, Leticia Vázquez-Cortés, Eusebio Perales-Rodríguez, Alicia Acosta-Espinoza, Yareni Perez-Lozano, Daniel Capdeville-García, Jorge Arturo Alatorre-Alexander
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 462-470 (2020)
PURPOSEThe LUME-Lung 1 study has brought consistent evidence of the effective use of nintedanib in lung adenocarcinoma as a second line of treatment; however, differences among ethnicities have been found in some studies.METHODSThis was a retrospecti
Externí odkaz:
https://doaj.org/article/9d217392ca9447fd9047653acf509678
Autor:
Alexandra Tyulyandina, Regina Berger, Diego Kaen, Mario E. Beiner, Jodi Alicia McKenzie, Lucy Gilbert, Elena Ioanna Braicu, Chel Hun Choi, John J Lee, Laura Farrelly, M Jesus Rubio, Vicky Makker, Christine M. Lee, Manuel Magallanes-Maciel, Kosei Hasegawa, Rafal Tarnawski, Sandro Pignata, Christian Marth, Sophia Frentzas, Christof Vulsteke, Xiaohua Wu
Publikováno v:
International Journal of Gynecological Cancer
International journal of gynecological cancer
International journal of gynecological cancer
BackgroundPembrolizumab plus lenvatinib is a novel combination with promising efficacy in patients with advanced and recurrent endometrial cancer. This combination demonstrated high objective response rates in a single-arm phase 1b/2 trial of lenvati
Autor:
Juan Paulo Ceja-García, Manuel Magallanes-Maciel, Noé Flores-Anaya, Valeria Michelle Fernández-Garibay, Daniel Capdeville-García, Jerónimo Rafael Rodríguez-Cid, Carlos Jose Zuloaga-Fernandez, Jorge Ignacio Gonzalez-Villanueva, Vanessa García-Montes, Luis Manuel Martínez-Barrera, Jorge Arturo Alatorre-Alexander, Eusebio Perales-Rodríguez, Saúl Campos-Gómez, Leticia Vázquez-Cortes, Claudia Rodríguez-Silva, Alberto Villalobos-Prieto, Iván Romarico González-Espinoza, Leopoldo Barriguete-Parra, Alicia Acosta-Espinoza, José Antonio Acevedo-Delgado, Juan Carlos Cázarez-Price, David Suárez-García, Roberto Kuri-Exsome, Yareni Perez-Lozano, Raquel Gerson-Cwilich, Rodrigo Rafael Flores-Mariñelarena, Alma Magdalena Astorga-Ramos, Maria Fernanda Noriega-Iriondo
Publikováno v:
JCO Global Oncology
PURPOSE The LUME-Lung 1 study has brought consistent evidence of the effective use of nintedanib in lung adenocarcinoma as a second line of treatment; however, differences among ethnicities have been found in some studies. METHODS This was a retrospe
Autor:
Roberto Sánchez-Reyes, Omar Castillo-Fernandez, C. Martin, Mariana Trigo, Jorge Otero, Eduardo Amieva-Rivera, Fernando Aldaco-Sarvide, Matthew Meyerson, Oscar Arrieta, Mauricio Cuello, Manuel Magallanes-Maciel, Alma D. Campos-Parra, L. Corrales-Rodriguez, Carlos Vargas, Luis Más-López, Juan Carlos Gómez de la Torre, Guillermo F. Bramuglia, Hernán Carranza, Andrés F. Cardona, Yanina Powazniak
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 10(5)
IntroductionPreviously, we reported the frequency of epidermal growth factor receptor (EGFR) and KRAS mutations in nonsmall-cell lung cancer (NSCLC) patients in Latin America. The EGFR mutation frequency was found between Asian (40%) and Caucasian (1